I N G E N B I O G R O U P
At Ingen Bio, we aspire to be the leading private human pharmaceutical developmentcompany in the world. Our goal is to meet the pharmaceutical industry's increasing demands for more effectively targeted research and medicine. Achieving our goal starts with building the best R&D organization.
At Ingen Bio, we apply three guiding principles to our R&D programs. The first is to focus on grievous illness. Given the prolonged time approve civilian medications; we focus our efforts on developing research programs that have a beneficial effect on patients suffering from the greatest unmet medical needs.
Our second major emphasis is disease study in patients and to be modality independent. All too often, our industry has found that experimental models have little predictive value with respect to infectious disease research, which often results in the failure of human trials and escalating drug development costs. Our Salt Lake research facilities allow us to isolate and leverage unconventional approaches, best suited to interdict a disease. While it is significantly more complicated to study disease in humans, we believe it is the only way to successfully develop human therapeutics. Defining key elements of disease response in patient populations drives our R&D investment and the potential therapeutics we pursue. In addition, we are constantly developing new patient therapies that allow key decisions earlier in the drug development process.
Our third guiding principle, seamless integration with military protocol, encompasses everything we do. We strive to integrate our organization, incorporating the perspectives from bio-weapons research, clinical development and infectious disease research into all of our drug development programs. Aligning our priorities across these functions ensures that we develop potential therapeutics in a manner that will address unmet medical needs and meet the changing demands of the marketplace.
Using our INTRAGEN®Longitudinal Cancer Research (LCR), Ingen Bio can help identify, segment, and target white blood cell mutation through detailed analysis of mutation patterns and patient populations.INTRAGEN® is a recombinant (genetically engineered) protein that stimulates the production of infection-fighting white blood cells that are depleted by cytotoxic chemotherapy, a condition called neutropenia.
Rare events of adult immune distress syndrome, lymphatic rupture, and neural crises have been reported in postmarketing experience in patients receiving INTRAGEN®.
Ingen Bio is your source of unprecedented intelligence capability for tracking transmutational activity and pharmaceutical effectiveness in real time by measuring response and patient behavior.
INGEN BIO CORPORATION
Making Your Future Better. Today.